Mechanistic Target of Rapamycin Complex 1
"Mechanistic Target of Rapamycin Complex 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An evolutionarily conserved multiprotein complex that functions as a cellular energy sensor and regulator of protein synthesis for cell growth and proliferation. It consists of TOR SERINE-THREONINE KINASES; REGULATORY-ASSOCIATED PROTEIN OF MTOR (RAPTOR); MLST8 PROTEIN; and AKT1 substrate 1 protein. The activity of the complex is regulated by SIROLIMUS; INSULIN; GROWTH FACTORS; PHOSPHATIDIC ACIDS; some amino acids or amino acid derivatives, and OXIDATIVE STRESS.
| Descriptor ID |
D000076222
|
| MeSH Number(s) |
D05.500.337 D08.811.913.696.620.682.700.931.500 D12.776.476.925.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 1".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 1".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 1" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 1 | 1 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 4 | 4 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 4 | 4 |
| 2018 | 0 | 2 | 2 |
| 2019 | 2 | 2 | 4 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 1" by people in Profiles.
-
Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease. Cells. 2021 09 02; 10(9).
-
CYLD exaggerates pressure overload-induced cardiomyopathy via suppressing autolysosome efflux in cardiomyocytes. J Mol Cell Cardiol. 2020 08; 145:59-73.
-
LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nat Cell Biol. 2020 02; 22(2):246-256.
-
Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20505-20510.
-
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors. Sci Adv. 2019 09; 5(9):eaax6352.
-
PKCa is required for Akt-mTORC1 activation in non-small cell lung carcinoma (NSCLC) with EGFR mutation. Oncogene. 2019 11; 38(48):7311-7328.
-
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019 03 21; 10(1):1296.
-
Systemic IL-6 regulation of eccentric contraction-induced muscle protein synthesis. Am J Physiol Cell Physiol. 2018 07 01; 315(1):C91-C103.
-
The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168. Nat Cell Biol. 2018 03; 20(3):320-331.
-
TFEB activation protects against cardiac proteotoxicity via increasing autophagic flux. J Mol Cell Cardiol. 2017 12; 113:51-62.